M. Véniant

GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
202514 citationsauthor #18
GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale
20254 citationsauthor #3
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
2024125 citationsauthor #1
A transcriptomic and proteomic atlas of obesity and type 2 diabetes in cynomolgus monkeys.
202310 citationsauthor #7
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
20235 citationsauthor #7
GIPR gene expression in testis is mouse specific and can impact male mouse fertility
20225 citationsauthor #6
A Transcriptomic and Proteomic Atlas of Obesity and Type 2 Diabetes in Cynomolgus Monkeys
20211 citationsauthor #6
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
202169 citationsauthor #17
Growth differentiation factor 15 as a potential therapeutic for treating obesity
202042 citationsauthor #2
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
2020109 citationsauthor #12
Mouse ECD with Fab1
20201 citationsauthor #17
The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: Characterization of the model and cardioprotective effect of GDF15
202020 citationsauthor #12
Cardiovascular response to small molecule APJ activation.
202041 citationsauthor #31
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
20206 citationsauthor #17
Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis
202021 citationsauthor #5
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?
201973 citationsauthor #5
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?
20191 citationsauthor #5
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
2018185 citationsauthor #25
FGF21 acts as a negative regulator of bile acid synthesis.
201849 citationsauthor #5
human GIPR ECD and Fab complex
20182 citationsauthor #25
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
2017194 citationsauthor #16
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
201755 citationsauthor #17
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward &bgr;-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
201788 citationsauthor #15
GPR21 KO mice demonstrate no resistance to high fat diet induced obesity or improved glucose tolerance
20169 citationsauthor #6
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties
201616 citationsauthor #6
FGF 21 is not a major mediator for bone homeostasis or metabolic actions of PPAR and PPAR agonists † Running Title : FGF 21 on bone and actions of PPAR PPAR
20160 citationsauthor #18
Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes
201620 citationsauthor #11
Molecular targeting of the GK-GKRP pathway in diabetes
201522 citationsauthor #4
Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.
2015198 citationsauthor #1
Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia
201541 citationsauthor #20
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
201412 citationsauthor #14
A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice
20141 citationsauthor #16
A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice
201417 citationsauthor #16
Characterization of a Novel Glucokinase Activator in Rat and Mouse Models
201420 citationsauthor #13
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors
201395 citationsauthor #28
Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase.
201316 citationsauthor #16
FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein
201366 citationsauthor #17
Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
2012143 citationsauthor #1
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
2012194 citationsauthor #7
Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex
2012212 citationsauthor #25
FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice
2012140 citationsauthor #1
An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice[S]
201216 citationsauthor #10
Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
2012160 citationsauthor #20
Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling
201299 citationsauthor #11
A Volumetric Method for Quantifying Atherosclerosis in Mice by Using MicroCT: Comparison to En Face
201129 citationsauthor #10
Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice
201133 citationsauthor #11
Lack of Overt FGF 21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
201118 citationsauthor #7
Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes.
201119 citationsauthor #11
Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
201054 citationsauthor #16
Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).
201081 citationsauthor #1
JPET # 157685 1 Long-term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control , with Reversibility of Alpha-Cell Hyperplasia and Hyperglucagonemia
20091 citationsauthor #14
Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia
200998 citationsauthor #15
Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis
200943 citationsauthor #11
Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice
2009110 citationsauthor #6
Pancreatic islet expression profiling in diabetes-prone C57BLKS/J mice reveals transcriptional differences contributed by DBA loci, including Plagl1 and Nnt
200937 citationsauthor #9
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
2009330 citationsauthor #16
MOL # 52852 14 Chronic Administration of 33 A Had No Effects on Body Weight and Food Intake in DIO Mouse Model
20090 citationsauthor #9
Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys
2009126 citationsauthor #19
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
20091,084 citationsauthor #16
Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice
200914 citationsauthor #8
Time of the day for 11β‐HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
200935 citationsauthor #1
An Acyl-Ghrelin-Specific Neutralizing Antibody Inhibits the Acute Ghrelin-Mediated Orexigenic Effects in Mice
200957 citationsauthor #9
FGF21 N‐ and C‐termini play different roles in receptor interaction and activation
2009163 citationsauthor #18
Dysregulation of Glucagon Secretion in Glucagon Receptor Null Pancreatic Islets
20081 citationsauthor #7
Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.
200836 citationsauthor #9
An optimized fast-performance liquid chromatography method for analyzing lipoprotein profiles using microliter volumes of serum.
20088 citationsauthor #4
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
200875 citationsauthor #15
Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.
200833 citationsauthor #1
Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model.
200825 citationsauthor #19
FGF21 Reverses Hepatic Steatosis, Increases Energy Expenditure and Improves Insulin Sensitivity in Diet-induced Obese Mice
200813 citationsauthor #17
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
200845 citationsauthor #19
Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling*
2007144 citationsauthor #11
Structural Characterization and Pharmacodynamic Effects of an Orally Active 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor
200734 citationsauthor #2
2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
200745 citationsauthor #10
Targeting Foxo1 in Mice Using Antisense Oligonucleotide Improves Hepatic and Peripheral Insulin Action
2006190 citationsauthor #12
Th-P16:329 The effect of leptin versus food restriction on lipid metabolism and atherosclerosis in ApoE-/-ApoB100/100OB-/- and LDLR-/-ApoB100/100 OB-/- mice
20064 citationsauthor #7
Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death
200492 citationsauthor #8
Leptin: from animals to humans.
200345 citationsauthor #1
mixed meal in type 2 diabetes Regulation of endogenous glucose production after a
20020 citationsauthor #48
Lipoprotein Secretion and Triglyceride Stores in the Heart*
200192 citationsauthor #2
Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.
2001150 citationsauthor #1
Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
2000118 citationsauthor #1
A Deficiency of Microsomal Triglyceride Transfer Protein Reduces Apolipoprotein B Secretion*
200075 citationsauthor #2
Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure.
19996 citationsauthor #2
Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice.
199925 citationsauthor #3
Insights into apolipoprotein B biology from transgenic and gene-targeted mice.
199931 citationsauthor #1
Lipoproteins containing apolipoprotein B-100 are secreted by the heart.
199918 citationsauthor #1
Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.
1999431 citationsauthor #2
Symposium : Assembly and Physiology of Apolipoprotein B – Containing Lipoproteins : Not Just for Heart Disease Anymore ! Insights into Apolipoprotein B Biology from Transgenic and Gene-Targeted Mice 1 , 2
19990 citationsauthor #1
Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene.
199848 citationsauthor #3
Using genetically engineered mice to understand apolipoprotein-B deficiency syndromes in humans.
199816 citationsauthor #3
Apo B100-containing lipoproteins are secreted by the heart.
1998127 citationsauthor #2
Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
1998164 citationsauthor #1
A Gene-targeted Mouse Model for Familial Hypobetalipoproteinemia
199823 citationsauthor #3
Walking Out on the Boys
199825 citationsauthor #8
Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes.
1998262 citationsauthor #5
A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet
1998207 citationsauthor #2
A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet
199833 citationsauthor #2
Effects of calcium blockade on end‐organ damage in experimental hypertension
199713 citationsauthor #3
Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
1997111 citationsauthor #1

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT